SCHEMBL309871

SCHEMBL309871

COc1cc(Br)cc(C(C)(C)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ALDH1A1 P00352 2/20 0.40
NOTUM Q6P988 1/20 0.36
CYP3A4 P08684 1/20 0.35
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
AOC3 Q16853 1/20 0.33
CYP1A1 P04798 2/20 0.32
CYP1B1 Q16678 2/20 0.32
GAA P10253 1/20 0.32
TTR P02766 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12024763 0.85 CA1 (0.42) CA1CA2ALDH1A1NOTUMCYP3A4
SCHEMBL3788801 0.84 ALDH1A1 (0.58) CA1CA2ALDH1A1CYP3A4MEN1
SCHEMBL5950375 0.84 ALDH1A1 (0.50) CA1CA2ALDH1A1CYP3A4MEN1
SCHEMBL15455484 0.82 CYP3A4 (0.37) ALDH1A1NOTUMCYP3A4HSD17B10
SCHEMBL4158265 0.82 CYP3A4 (0.37) ALDH1A1NOTUMCYP3A4HSD17B10
SCHEMBL20380281 0.81 NOTUM (0.39) CA1CA2NOTUMMAPTABL1
SCHEMBL5783571 0.79 NOTUM (0.51) ALDH1A1NOTUMMAPTRAB9ANPSR1
SCHEMBL29427065 0.79 NOTUM (0.51) ALDH1A1NOTUMMAPTRAB9ANPSR1
SCHEMBL16492983 0.78 CYP3A4 (0.41) ALDH1A1CYP3A4MEN1LMNAKMT2A
SCHEMBL309832 0.77 ALDH1A1 (0.59) CA1CA2ALDH1A1CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
EP-2303857-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS Novartis AG (CH) 2011-04-06 EP disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed
WO-2010003976-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors BACE2, BACE1, APP CA1 169/4885CA2 101/4885ALDH1A1 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.